Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Their platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within their three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Their platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of their first PBTs and their novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Avadim Technologies or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.